WHAT IS CLAIMED IS:

1. Use of oxaliplatin and capecitabine in the manufacture of a drug for treating gastric cancer in a subject or reducing viability of gastric cancer cells, wherein:

the oxaliplatin and capecitabine are to be administered to the subject; or the cancer cells, and

an alternating electric field is to be applied to a target region of the subject or the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz.

2. The use of claim 1, wherein at least a portion of the alternating electric field is to be applied after administration of the oxaliplatin and capecitabine and before the oxaliplatin and capecitabine are eliminated from the subject's body.

3. The use of claim 1, wherein the alternating electric field is to be applied for a duration of at least 72 hours.

4. The use of claim 1, wherein the frequency of the alternating electric field is between 120 and 180 kHz.

5. The use of claim 1, wherein the frequency of the alternating electric field is between 145 and 155 kHz.

6. The use of claim 1, wherein the oxaliplatin and capecitabine are to be administered at therapeutically effective doses, and the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the target region.

7. The use of claim 6, wherein the alternating electric field is to be applied for a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 120 and 180 kHz.

8. The use of claim 6, wherein the alternating electric field is to be applied for a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 145 and 155 kHz.

9. The use of claim 1, wherein at least a portion of the alternating electric field is applied simultaneously with the administration of oxaliplatin and capecitabine.

10. The use of claim 1, wherein each of the oxaliplatin and capecitabine is delivered to the cancer cells at a therapeutically effective concentration, and the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells.

11. The use of claim 10, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 120 and 180 kHz.

12. The use of claim 10, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 145 and 155 kHz.

13. Use of folinic acid, fluorouracil and oxaliplatin in the manufacture of a drug for treating gastric cancer in a subject or reducing viability of gastric cancer cells, wherein:

the folinic acid, fluorouracil, and oxaliplatin are to be administered to the subject or the cancer cells; and

an alternating electric field is to be applied to a target region of the subject or the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz.

14. The use of claim 13, wherein at least a portion of the applying is performed after the administering and before the folinic acid, fluorouracil, and oxaliplatin are eliminated from the subject's body.

15. The use of claim 14, wherein the alternating electric field is to be applied for a duration of at least 72 hours.

16. The use of claim 13, wherein the frequency of the alternating electric field is between 120 and 180 kHz.

17. The use of claim 13, wherein the frequency of the alternating electric field is between 145 and 155 kHz.

18. The use of claim 13, wherein the folinic acid, fluorouracil, and oxaliplatin are to be administered at therapeutically effective doses, and the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the target region.

19. The use of claim 18, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 120 and 180 kHz.

20. The use of claim 18, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 145 and 155 kHz.

21. The use of claim 13, wherein at least a portion of the alternating electric field is to be applied simultaneously with administration of at least a portion of the folinic acid, fluorouracil and oxaliplatin.

22. The use of claim 13, wherein each of the folinic acid, fluorouracil, and oxaliplatin is to be delivered to the cancer cells at a therapeutically effective concentration, and the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells.

23. The use of claim 22, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 120 and 180 kHz.

24. The use of claim 22, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 145 and 155 kHz.

25. Use of fluorouracil in the manufacture of a drug for treating gastric cancer or reducing viability of gastric cancer cells in a subject or reducing the viability of gastric cancer cells, wherein,

fluorouracil is to be administered to the subject; and

an alternating electric field is to be applied to a target region of the subject, the alternating electric field having a frequency between 100 and 400 kHz.

26. The use of claim 25, wherein at least a portion of the alternating electric field is to be applied after the administration of fluorouracil and before the fluorouracil is eliminated from the subject's body or exhausted.

27. The use of claim 25, wherein the alternating electric field is to be applied for a duration of at least 72 hours.

28. The use of claim 25, wherein the frequency of the alternating electric field is between 120 and 180 kHz.

29. The use of claim 25, wherein the frequency of the alternating electric field is between 145 and 155 kHz.

30. The use of 25, wherein the fluorouracil is to be administered at a therapeutically effective dose, and the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the target region.

31. The use of claim 25, wherein the fluorouracil is to be administered by direct administration of the fluorouracil to the subject.

32. The use of claim 25, wherein the fluorouracil is to be administered by indirect administration of the fluorouracil to the subject.

33. The use of claim 32, wherein the indirect administration of the fluorouracil is accomplished by administering a pre-prodrug to the subject, wherein the pre-prodrug is converted to fluorouracil in the subject's body.

34. The use of claim 33, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 120 and 180 kHz.

35. The use of claim 33, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 145 and 155 kHz.

36. The use of claim 25, wherein at least a portion of the alternating electric field is to be applied simultaneously with at least a portion of the administration of the fluorouracil.

37. The use of claim 25, wherein the fluorouracil is to be administered to the cancer cells at a therapeutically effective concentration, and the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells.

38. The use of claim 37, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 120 and 180 kHz.

39. The use of claim 37, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 145 and 155 kHz.